Association of ICP, CPP, CT findings and S-100B and NSE in severe traumatic head injury. Prognostic value of the biomarkers

Brain Injury

Volumn 29, Issue 4, 2015, Pages 446-454

  Olivecrona, Zandra ^a   Bobinski, Lukas ^a   Koskinen, Lars Owe D ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

CPP; CT classification; ICP; ICP targeted therapy; NSE; Prognostication; S 100B; Severe traumatic brain injury

Indexed keywords

NEURON SPECIFIC ENOLASE; PROTEIN S100B; BIOLOGICAL MARKER; ENOLASE; S100B PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN PERFUSION; BRAIN PERFUSION PRESSURE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; GLASGOW COMA SCALE; GLASGOW OUTCOME SCALE; HUMAN; INJURY SEVERITY; INTRACRANIAL PRESSURE; MALE; NEUROIMAGING; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRAUMATIC BRAIN INJURY; BLOOD; BRAIN CIRCULATION; BRAIN INJURY; CLINICAL TRIAL; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ADOLESCENT; ADULT; AGED; BIOMARKERS; BRAIN INJURIES; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; INTRACRANIAL PRESSURE; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928014432     PISSN: 02699052     EISSN: 1362301X     Source Type: Journal    
DOI: 10.3109/02699052.2014.989403     Document Type: Article

References (65)

1. Kleindienst A, Ross Bullock M. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. Journal of Neurotrauma 2006;23:1185-1200.
2. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997;28:1956-1960.
3. Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A. Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochirurgica 1997;139:1161-1164.
4. Wiesmann M, Missler U, Hagenström H, Gottmann D. S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochirurgica 1997;139:1155-1160.
5. Ytrebø LM, Ingebrigtsen T, Nedredal GI, Elvenes OP, Korvald C, Romner B, Revhaug A. Protein S-100beta: A biochemical marker for increased intracranial pressure in pigs with acute hepatic failure. Scandinavian Journal of Gastroenterology 2000;35:546-551.
6. Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. British Journal of Neurosurgery 1999;13:56-59.
7. Johnsson P, Blomquist S, Lührs C, Malmkvist G, Alling C, Solem JO, Stahl E. Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation. The Annals of Thoracic Surgery 2000;69:750-754.
8. Herrmann M, Jost S, Kutz S, Ebert AD, Kratz T, Wunderlich MT, Synowitz H. Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. Journal of Neurotrauma 2000;17:113-122.
9. Ingebrigtsen T, Romner B, Trumpy JH. Management of minor head injury: The value of early computed tomography and serum protein S-100 measurements. Journal of Clinical Neuroscience 1997;4: 29-33.
10. Müller K, Townend W, Biasca N, Undén J, Waterloo K, Romner B, Ingebrigtsen T. S100B serum level predicts computed tomography findings after minor head injury. Journal of Trauma 2007;62: 1452-1456.
11. Romner B, Ingebrigtsen T, Kongstad P, Børgesen SE. Traumatic brain damage: Serum S-100 protein measurements related to neuroradiological findings. Journal of Neurotrauma 2000;17: 641-647.
12. Murillo-Cabezas F, Muñoz-Sánchez MÁ, Rincón-Ferrari MD, Martín-Rodríguez JF, Amaya-Villar R, García-Gómez S, Leon- Carrion J. The prognostic value of the temporal course of S100b protein in post-acute severe brain injury: A prospective and observational study. Brain Injury 2010;24:609-619.
13. Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocritical Care 2007;6:121-138.
14. Kövesdi E, Lückl J, Bukovics P, Farkas O, Pál J, Czeiter E, Szellár D, Dóczi T, Komoly S, Buki A. Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochirurgica 2009;152:1-17.
15. Olivecrona M, Rodling-Wahlström M, Naredi S, Koskinen L-OD. S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. Journal of Neurology, Neurosurgery and Psychiatry 2009;80:1241-1247.
16. Mercier E, Boutin A, Lauzier F, Fergusson DA, Simard J-F, Zarychanski R, Moore L, McIntyre LA, Archambault P, Lamontagne F, et al. Predictive value of S-100b protein for prognosis in patients with moderate and severe traumatic brain injury: Systematic review and meta-analysis. British Medica Journal 2013;346:f1757-f1757.
17. Olivecrona Z, Koskinen L-OD. The release of S-100B and NSE in severe traumatic head injury is associated with APOE "4. Acta Neurochirurgica 2012;154:675-680.
18. Kofke WA, Konitzer P, Meng QC, Guo J, Cheung A. The effect of apolipoprotein E genotype on neuron specific enolase and S-100beta levels after cardiac surgery. Anesthesia and Analgesia 2004;99:1323-1325.
19. Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V. Serum S- 100B protein in severe head injury. Neurosurgery 1999;45: 477-483.
20. Woertgen C, Rothoerl RD, Metz C, Brawanski A. Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. Journal of Trauma 1999;47:1126-1130.
21. Hayakata T, Shiozaki T, Tasaki O, Ikegawa H, Inoue Y, Toshiyuki F, Hosotubo H, Kieko F, Yamashita T, Tanaka H, et al. Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 2004;22:102-107.
22. Pelinka LE, Toegel E, Mauritz W, Redl H. Serum S 100 B: A marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 2003;19:195-200.
23. Thelin EP, Nelson DW, Bellander BM. Secondary peaks of S100B in serum relate to subsequent radiological pathology in traumatic brain injury. Neurocritical Care 2014;20:217-229.
24. Marshall LF, Bowers Marshall S, Klauber MR, van Berkum Clark M, Eisenberg HM, Jane JA, Luerssen TG, Marmarou A, Foulkes MA. A new classification of head injury based on computerized tomography. Journal of Neurosurgery 1991;75:14-20.
25. Maas AIR, Hukkelhoven CWPM, Marshall LF, Steyerberg EW. Prediction of outcome in traumatic brain injury with computed tomographic characteristics: A comparison between the computed tomographic classification and combinations of computed tomographic predictors. Neurosurgery 2005;57:1173-1182.
26. Morris GF, Marshall LF. A new, practical classification of traumatic subarachnoid hemorrhage. Clinical Neurology and Neurosurgery 1997;99(Suppl. 1):S16.
27. Bobinski L, Olivecrona M, Koskinen L-OD. Dynamics of brain tissue changes induced by traumatic brain injury assessed with the Marshall, Morris-Marshall, and the Rotterdam classifications and its impact on outcome in a prostacyclin placebo-controlled study. Acta Neurochirurgica 2012;154:1069-1079.
28. Gradisek P, Osredkar J, Korsic M, Kremzar B. Multiple indicators model of long-term mortality in traumatic brain injury. Brain Injury 2012;26:1472-1481.
29. Lesko MM, O'Brien SJ, Childs C, Bouamra O, Rainey T, Lecky F. Comparison of several prognostic tools in traumatic brain injury including S100B. Brain Injury 2014;28:987-994.
30. Olivecrona M, Rodling-Wahlström M, Naredi S, Koskinen L-OD. Prostacyclin treatment in severe traumatic brain injury: A microdialysis and outcome study. Journal of Neurotrauma 2009; 26:1251-1262.
31. Baker SP, O'Neill B, Haddon W, Long WB. The injury severity score: A method for describing patients with multiple injuries and evaluating emergency care. Journal of Trauma 1974;14:187-196.
32. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: Guidelines for their use. Journal of Neurotrauma 1998;15: 573-585.
33. Olivecrona M, Rodling-Wahlström M, Naredi S, Koskinen L-OD. Prostacyclin treatment and clinical outcome in severe traumatic brain injury patients managed with an ICP-targeted therapy: A prospective study. Brain Injury 2012;26:67-75.
34. Olivecrona Z, Dahlqvist P, Koskinen L-OD. Acute neuro-endocrine profile and prediction of outcome after severe brain injury. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2013;21:33.
35. Grände P-O, Möller AD, Nordström C-H, Ungerstedt U. Low-dose prostacyclin in treatment of severe brain trauma evaluated with microdialysis and jugular bulb oxygen measurements. Acta Anaesthesiologica Scandinavica 2000;44:886-894.
36. Möller AD, Grände P-O. Low-dose prostacyclin has potent capillary permeability-reducing effect in cat skeletal muscle in vivo. American Journal of Physiology 1997;273:H200-H207.
37. Koskinen L-OD, Eklund A, Sundström N, Olivecrona M. Prostacyclin influences the pressure reactivity in patients with severe traumatic brain injury treated with an ICP-Targeted Therapy. Neurocritical Care 2014; DOI. 10.1007/s12028-014-0030-8.
38. Wiesmann M, Missler U, Gottmann D, Gehring S. Plasma S-100b protein concentration in healthy adults is age- and sex-independent. Clinical Chemistry 1998;44:1056-1058.
39. Barzó P, Marmarou A, Fatouros P, Corwin F, Dunbar J. Magnetic resonance imaging-monitored acute blood-brain barrier changes in experimental traumatic brain injury. Journal of Neurosurgery 1996; 85:1113-1121.
40. Marmarou A, Portella G, Barzó P, Signoretti S, Fatouros P, Beaumont A, Jiang T, Bullock R. Distinguishing between cellular and vasogenic edema in head injured patients with focal lesions using magnetic resonance imaging. Acta Neurochirurgica Suppl 2000;76:349-351.
41. Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Aumayr B, Vogelbaum MA, et al. Serum S100beta: A noninvasive marker of blood-brain barrier function and brain lesions. Cancer 2003;97:2806-2813.
42. Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR, Kanner A, Ayumar B, Albensi B, Cavaglia M, et al. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restorative Neurology and Neuroscience 2003;21:109-121.
43. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G. High serum S100B levels for trauma patients without head injuries. Neurosurgery 2001;48:1255-1258.
44. da Rocha AB, Schneider RF, de Freitas GR, André C, Grivicich I, Zanoni C, Fossa A, Gehrke JT, Pereira Jotz G, Kaufmann M, et al. Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males. Clinical Chemistry and Laboratory Medicine 2006;44:1234-1242.
45. Thelin EP, Johannesson L, Nelson D, Bellander BM. S100B is an important outcome predictor in traumatic brain injury. Journal of Neurotrauma 2013;30:519-528.
46. Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RSB, Ruppel RA, Kochanek PM. Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 2002;109:E31.
47. Wu H-M, Huang S-C, Hattori N, Glenn TC, Vespa PM, Yu C-L, Hovda DA, Phelps ME, Bergsneider M. Selective metabolic reduction in gray matter acutely following human traumatic brain injury. Journal of Neurotrauma 2004;21:149-161.
48. Bandyopadhyay S, Hennes H, Gorelick MH, Wells RG, Walsh-Kelly CM. Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury. Academic Emergency Medicine 2005;12:732-738.
49. Nygaard O, Langbakk B, Romner B. Neuron-specific enolase concentrations in serum and cerebrospinal fluid in patients with no previous history of neurological disorder. Scandinavian Journal of Clinical and Laboratory Investigation 1998;58:183-186.
50. Hans VH, Kossmann T, Lenzlinger PM, Probstmeier R, Imhof HG, Trentz O, Morganti-Kossmann MC. Experimental axonal injury triggers interleukin-6 mRNA, protein synthesis and release into cerebrospinal fluid. Journal of Cerebral Blood Flow and Metabolism 1999;19:184-194.
51. Undén J, Astrand R, Waterloo K, Ingebrigtsen T, Bellner J, Reinstrup P, Andsberg G, Romner B. Clinical significance of serum S100B levels in neurointensive care. Neurocritical Care 2007;6: 94-99.
52. Kirchhoff C, Buhmann S, Braunstein V, Leidel BA, Vogel T, Kreimeier U, Mutschler W, Biberthaler P. Cerebrospinal s100-B: A potential marker for progressive intracranial hemorrhage in patients with severe traumatic brain injury. European Journal of Medical Research 2008;13:511-516.
53. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: Relationship to brain damage and outcome. Journal of Neurotrauma 2004;21:1553-1561.
54. Stein DM, Kufera JA, Lindell A, Murdock KR, Menaker J, Bochicchio GV, Aarabi B, Scalea TM. Association of CSF biomarkers and secondary insults following severe traumatic brain injury. Neurocritical Care 2011;14:200-207.
55. Raabe A, Seifert V. Fatal secondary increase in serum S-100B protein after severe head injury. Report of three cases. Journal of Neurosurgery 1999;91:875-877.
56. Vos PE, van Gils M, Beems T, Zimmerman C, Verbeek MM. Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity. European Journal of Neurology 2006;13:632-638.
57. Jung CS, Lange B, Zimmermann M, Seifert V. CSF and serum biomarkers focusing on cerebral vasospasm and ischemia after subarachnoid hemorrhage. Stroke Research and Treatment 2013; 2013:560305.
58. Babcock L, Byczkowski T, Mookerjee S, Bazarian JJ. Ability of S100B to predict severity and cranial CT results in children with TBI. Brain Injury 2012;26:1372-1380.
59. Undén J, Romner B. Can low serum levels of S100B predict normal CT findings after minor head injury in adults?: An evidence-based review and meta-analysis. Journal of Head Trauma Rehabilitation 2010;25:228-240.
60. Bouzat P, Francony G, Declety P, Brun J, Kaddour A, Renversez J-C, Jacquot C, Payen JF. [Can serum protein S100beta predict neurological deterioration after moderate or minor traumatic brain injury?]. Annales Françaises d'Anesthesie et de Reanimation 2009; 28:135-139.
61. Piazza O, Storti MP, Cotena S, Stoppa F, Perrotta D, Esposito G, Pirozzi N, Tufano R. S100B is not a reliable prognostic index in paediatric TBI. Pediatric Neurosurgery 2007;43:258-264.
62. Ross SA, Cunningham RT, Johnston CF, Rowlands BJ. Neuronspecific enolase as an aid to outcome prediction in head injury. British Journal of Neurosurgery 1996;10:471-476.
63. Guan W, Yang Y-L, Xia W-M, Li L, Gong D-S. Significance of serum neuron-specific enolase in patients with acute traumatic brain injury. Chinese Journal of Traumatology 2003;6: 218-221.
64. Vos PE, Jacobs B, Andriessen TMJC, Lamers KJB, Borm GF, Beems T, Edwards M, Rosmalen CF, Vissers JLM. GFAP and S100B are biomarkers of traumatic brain injury: An observational cohort study. Neurology 2010;75:1786-1793.
65. Kapural M, Krizanac-Bengez L, Barnett G, Perl J, Masaryk T, Apollo D, Rasmussen P, Mayberg MR, Janigro D. Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Research 2002;940:102-104.